ORAL FILM DRUG DELIVERY SYSTEMS FOR BETAHISTINE DIHYDROCHLORIDE: CURRENT PERSPECTIVES AND FUTURE DIRECTIONS
DOI:
https://doi.org/10.53555/emmkpe35Keywords:
Fast Dissolving drug delivery system, Oral Thin Film, Super disintegrants, Dissolution, DisintegrationAbstract
The development of fast-dissolving oral thin films has recently followed the progression of dosage forms from straight forward ordinary tablets and capsules to modified release tablets and capsules, oral disintegrating tablets, and wafers. A hydrophilic polymer used in fast- dissolving oral thin films quickly hydrates or adheres when applied on the tongue or in buccal cavity. These films melt or disintegrate in a matter of seconds, releasing the active ingredient without need for drinking or chewing. A drug-containing thin film with surface area of 5 to 20 cm2 is called an oral dissolving film. The maximum single dose of the drugs that can be loaded is 30mg. As opposed to tablets, several pharmaceutical companies are now producing oral thin films that dissolve quickly. Films combine the benefits of liquid dosage forms with those of tablets, such as exact dose and simple administration (easy swallowing, rapid bioavailability. At the same time, it gives a general overview of crucial formulation design factors that have an impact on thin films, such as thin film design, anatomical and physiological constraints, choice of the best manufacturing processes, characterization techniques, and the physicochemical properties of drugs and polymers. Fast-dissolving or al thin films can be used for a variety of purposes, including sublingual and gastro-retentive delivery systems in addition to buccal fast-dissolving systems. Future uses might involve employing laminated multilayer films to combine incompatible active medicinal components into a single product.
References
1.Mishra R, Amin A. Formulation and characterization of rapidly dissolving oral thin films of cetirizine hydrochloride. Int J Pharm Pharm Sci. 2011;3(1):106–110.
2.Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug delivery. J Control Release. 2011;153(2):106–116.
3.Preis M, Pein M, Breitkreutz J. Development of a taste-masked orodispersible film containing dimenhydrinate. Pharmaceutics. 2012;4(4):551–562.
4.Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013;3(2):67–76.
5.U.S. Food and Drug Administration. Guidance for Industry: Orally Disintegrating Tablets. FDA; 2008.
6.Irfan M, Rabel S, Bukhtar Q, et al. Orally disintegrating films: A modern expansion in drug delivery system. Saudi Pharm J. 2016;24(5):537–546.
7.Hoffmann EM, Breitenbach A, Breitkreutz J. Advances in orodispersible films for drug delivery. Expert Opin Drug Deliv. 2011;8(3):299–316.
8.Kalyan S, Bansal M. Recent trends in the development of oral dissolving film. Int J PharmTech Res. 2012;4(2):725–733.
9.Peh KK, Wong CF. Polymeric films as vehicle for buccal delivery: Swelling, mechanical, and bioadhesive properties. J Pharm Pharm Sci. 1999;2(2):53–61.
10.Bhyan B, Jangra S, Kaur M, Singh H. Orally fast dissolving films: Innovations in formulation and technology. Int J Pharm Sci Rev Res. 2011;9(2):50–57.
11.Lacour M, van de Heyning PH, Novotny M, Tighilet B. Betahistine in the treatment of Ménière’s disease. Neuropsychiatr Dis Treat. 2007;3(4):429–440.
12.Jeck-Thole S, Wagner W. Betahistine: A retrospective synopsis of safety data. Drug Saf. 2006;29(11):1049–1059.
13.Strupp M, Hupert D, Frenzel C, et al. Long-term prophylactic treatment of attacks of vertigo in Ménière’s disease—Comparison of high and low dosage betahistine. J Neurol. 2008;255(5):701–706.
14.Tighilet B, Trottier S, Mourre C, Lacour M. Betahistine dihydrochloride interaction with histamine receptors in the cat: Neurochemical and behavioral effects. Eur J Pharmacol. 2007;559(2–3):192–200.
15.Nuti D, Masini M, Mandalà M. Pharmacological management of vertigo. CNS Drugs. 2013;27(8):617–636.
16.Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 6th ed. London: Pharmaceutical Press; 2009.
17.Felton LA. Mechanisms of polymeric film formation. Int J Pharm. 2013;457(2):423–427.
18.Perumal VA, Lutchman D, Mackraj I, Govender T. Formulation of buccal films with mucoadhesive properties. Int J Pharm. 2008;361(1–2):150–155.
19.Cilurzo F, Cupone IE, Minghetti P, Buratti S, Selmin F, Montanari L. Nicotine fast dissolving films made of maltodextrins: A feasibility study. AAPS PharmSciTech. 2010;11(4):1511–1517.
20.Senta-Loys Z, Bourgeois S, Valour JP, Briançon S, Fessi H. Orodispersible films: A review of formulation and manufacturing processes. Drug Dev Ind Pharm. 2017;43(1):1–15.
21.Shojaei AH. Buccal mucosa as a route for systemic drug delivery: A review. J Pharm Pharm Sci. 1998;1(1):15–30.
22.Khairnar A, Jain P, Baviskar D, Jain D. Development of oral dissolving films for drug delivery: A review. Asian J Pharm. 2012;6(4):281–289.
23.Preis M. Orally disintegrating films and mini-tablets—Innovative dosage forms of choice for pediatric use. AAPS PharmSciTech. 2015;16(2):234–241.
24.Anand V, Kataria M, Kukkar V, Saharan V, Choudhury PK. The latest trends in the taste assessment of pharmaceuticals. Drug Discov Today. 2007;12(5–6):257–265.
25.Morales JO, Brayden DJ. Buccal delivery of small molecules and biologics: Of mucoadhesive polymers, films, and nanoparticles. Curr OpinPharmacol. 2017; 36:22–28.
26.Patel AR, Prajapati DS, Raval JA. Fast dissolving films as a new venture in fast dissolving dosage forms. Int J Drug Dev Res. 2010;2(2):232–246.
27.Musazzi UM, Selmin F, Ortenzi MA, et al. Personalized orodispersible films by hot-melt ram extrusion. Int J Pharm. 2018;551(1–2):52–59.
28.Preis M, Knop K, Breitkreutz J. Mechanical strength test for orodispersible films. Int J Pharm. 2014;461(1–2):22–29.
29.Thabet Y, Lunter D, Breitkreutz J. Continuous manufacturing of orodispersible films. Eur J Pharm Biopharm. 2018;126:1–7.
